Results 281 to 290 of about 43,876 (313)
Some of the next articles are maybe not open access.
Therapeutic Drug Monitoring, 2016
In humans, donepezil (D) is metabolized to 5-O-desmethyl-donepezil (5DD), 6-O-desmethyl-donepezil (6DD), and donepezil-N-oxide (DNox). Although 6DD and DNox are pharmacologically active, the activity of 5DD is unknown. At present, no routine methods are available to detect D and its 3 metabolites simultaneously.
Groppa, Francesca +6 more
openaire +4 more sources
In humans, donepezil (D) is metabolized to 5-O-desmethyl-donepezil (5DD), 6-O-desmethyl-donepezil (6DD), and donepezil-N-oxide (DNox). Although 6DD and DNox are pharmacologically active, the activity of 5DD is unknown. At present, no routine methods are available to detect D and its 3 metabolites simultaneously.
Groppa, Francesca +6 more
openaire +4 more sources
The Consultant Pharmacist, 2014
To report a case of mania associated with the titration of donepezil in an elderly patient.A 400-bed academic acute care psychiatric facility.A 70-year-old male with a history of paranoid schizophrenia, alcohol dependence, and mild cognitive impairment was admitted after concerns that he was responding to internal stimuli and exhibited increased ...
openaire +3 more sources
To report a case of mania associated with the titration of donepezil in an elderly patient.A 400-bed academic acute care psychiatric facility.A 70-year-old male with a history of paranoid schizophrenia, alcohol dependence, and mild cognitive impairment was admitted after concerns that he was responding to internal stimuli and exhibited increased ...
openaire +3 more sources
2003
Donepezil is the second cholinesterase inhibitor to have become commercially available. It is considered a “second-generation” acetylcholinesterase inhibitor (AChEI) because of its safety profile with clear advantages over the acridine-based cholinesterase inhibitor tacrine, the first AChEI approved for symptomatic treatment of Alzheimer’s disease (AD).
Howard H. Feldman +1 more
openaire +2 more sources
Donepezil is the second cholinesterase inhibitor to have become commercially available. It is considered a “second-generation” acetylcholinesterase inhibitor (AChEI) because of its safety profile with clear advantages over the acridine-based cholinesterase inhibitor tacrine, the first AChEI approved for symptomatic treatment of Alzheimer’s disease (AD).
Howard H. Feldman +1 more
openaire +2 more sources
Donepezil Use in Alzheimer Disease
Annals of Pharmacotherapy, 1998OBJECTIVE To review the pharmacology, pharmacokinetics, clinical efficacy, adverse effects, drug–drug interactions, and the therapeutic issues concerning the use of donepezil in patients with Alzheimer disease. DATA SOURCES Published articles and abstracts in English were identified by MEDLINE (January 1985–July 1997) searches using the search terms ...
Shelly L. Gray, Erica L Barner
openaire +3 more sources
Classics in Chemical Neuroscience: Donepezil
ACS Chemical Neuroscience, 2018The discovery of acetylcholine and acetylcholinesterase provided the first insight into the intricacies of chemical signal transduction and neuronal communication. Further elucidation of the underlying mechanisms led to an attendant leveraging of this knowledge via the synthesis of new therapeutics designed to control aberrant biochemical processes ...
James T. Brewster +3 more
openaire +4 more sources
Journal of the American Medical Association (JAMA), 2004
CONTEXT Memantine is a low- to moderate-affinity, uncompetitive N-methyl-D-aspartate receptor antagonist. Controlled trials have demonstrated the safety and efficacy of memantine monotherapy for patients with moderate to severe Alzheimer disease (AD) but
P. Tariot +5 more
semanticscholar +1 more source
CONTEXT Memantine is a low- to moderate-affinity, uncompetitive N-methyl-D-aspartate receptor antagonist. Controlled trials have demonstrated the safety and efficacy of memantine monotherapy for patients with moderate to severe Alzheimer disease (AD) but
P. Tariot +5 more
semanticscholar +1 more source
Donepezil for memory dysfunction in schizophrenia
Journal of Psychopharmacology, 2002A case is reported of a 54-year-old female patient with schizophrenia and cognitive impairment. Her memory dysfunction improved following the addition of donepezil to quetiapine. The possible implications for future studies are reviewed.
Allen E. Thornton +3 more
openaire +3 more sources
Donepezil for mild cognitive impairment
Cochrane Database of Systematic Reviews, 2006Problems with memory which do not meet the diagnostic criteria for dementia, usually called mild cognitive impairment (MCI), can be the first sign of an impending dementia, particularly Alzheimer's disease (AD). There is no consensus on a definition or diagnostic criteria for MCI, and MCI remains a vague term and those so described are a heterogeneous ...
Leon Flicker, Jacqueline Birks
openaire +3 more sources